# Pediatrix Medical Group Reports First Quarter Results
Canonical URL: https://biopharmsignal.com/news/MD/pediatrix-medical-group-reports-first-quarter-results
Ticker: MD
Company: Pediatrix Medical Group, Inc.
Source: Pediatrix Medical Group, Inc.
Published: 2026-05-05 10:00 EST
Original Source URL: https://mednax.gcs-web.com
## Summary

FORT LAUDERDALE, Fla. --(BUSINESS WIRE)--May 5, 2026-- Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44.

## Article Body
FORT LAUDERDALE, Fla. --(BUSINESS WIRE)--May 5, 2026-- Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44.
## Recent Company News
- 2026-06-03 20:30 EST — [Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology](https://biopharmsignal.com/news/MD/pediatrix-medical-group-announces-publication-of-new-research-addressing-urgent-questions-in-neonatology) — Source: Pediatrix Medical Group, Inc.
- 2026-05-05 10:00 EST — [Pediatrix Medical Group Reports First Quarter Results](https://biopharmsignal.com/news/MD/pediatrix-medical-group-reports-first-quarter-results) — Source: Pediatrix Medical Group, Inc.
- 2026-04-20 10:45 EST — [Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026](https://biopharmsignal.com/news/MD/pediatrix-medical-group-2026-first-quarter-conference-call-webcast-scheduled-for-tuesday-may-5-2026) — Source: Pediatrix Medical Group, Inc.
- 2026-03-26 20:30 EST — [Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine](https://biopharmsignal.com/news/MD/pediatrix-expands-maternal-health-services-in-tennessee-in-partnership-with-tennessee-maternal-fetal-medicine) — Source: Pediatrix Medical Group, Inc.
- 2026-03-24 21:10 EST — [Pediatrix Welcomes Two Nationally Renowned Physician Leaders](https://biopharmsignal.com/news/MD/pediatrix-welcomes-two-nationally-renowned-physician-leaders) — Source: Pediatrix Medical Group, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)